LexisNexis Risk Solutions,
adamprogram.com
A New Interactive Tool Empowers the Public to Search Geo-Targeted Missing Children Alerts Being Distributed Through the ADAM Program. The Dashboard Was Released in Honor of National Missing Children’s Day.
Elsevier, Neuron, Volume 113, 7 May 2025
Changes in β-amyloid (Aβ) and hyperphosphorylated tau (T) in brain and cerebrospinal fluid (CSF) precede Alzheimer's disease (AD) symptoms, making the CSF proteome a potential avenue to understand disease pathophysiology and facilitate reliable diagnostics and therapies. Using the AT framework and a three-stage study design (discovery, replication, and meta-analysis), we identified 2,173 analytes (2,029 unique proteins) dysregulated in AD. Of these, 865 (43%) were previously reported, and 1,164 (57%) are novel.
Elsevier,
Pharmacological Research, Volume 215, May 2025
The article discusses the role of gut dysbiosis, bacterial amyloids, and metabolic diseases in the development and progression of Alzheimer's disease (AD). It highlights the bidirectional relationship between the gut microbiome, inflammation, and metabolic disorders, and how these interconnected pathways contribute to neurodegeneration. The review explores potential therapeutic strategies targeting the gut-brain-metabolic axis to mitigate AD progression.
Elsevier,
Journal of Communication Disorders, Volume 115, 1 May 2025
This systematic review examined the relationship between cognition and motor speech production in healthy older adults and those with mild cognitive impairment, analyzing 22 studies with 747 participants. Findings suggest that cognitive functions, particularly attention and executive abilities, are linked to motor speech performance, though evidence quality varies and gaps remain.
Elsevier,
Pharmacological Research, Volume 215, May 2025
The article provides a comprehensive review of the role of semaphorin 3A (Sema3A) in the pathogenesis and progression of Alzheimer's disease and other aging-related diseases. It discusses the expression patterns and mechanisms of action of Sema3A in various age-related disorders, including its involvement in oxidative stress, inflammatory responses, apoptosis, and synaptic plasticity.
Elsevier,
Med, Volume 6, 9 May 2025
Real-world evidence can supplement clinical trial data to optimize Alzheimer’s disease care by aiding early patient identification and assessing drug effectiveness and safety in everyday use in diverse clinical settings/populations. This information helps inform clinical practice guidelines and supports the development of tools for timely diagnosis and personalized treatment strategies.
